secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2022-11-22T23:59:59+00:00
Accession:  0001193125-22-290244
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graybug to merge with CalciMedica; combined company focused on Auxora for inflammatory diseases
--------------------------------------------------------------------------------

- Graybug holders to own ~29% of combined co; CalciMedica holders ~71% (based on $40M and $100M valuations).
- Combined co expected to have ~$35M cash at close, with runway into H2 2024; includes ~$10.3M private placement.
- Auxora Phase 2b AP data expected H2 2023; Phase 1/2 AAP data H1 2023; potential accelerated approval path.
- Rachel Leheny (CalciMedica CEO) to lead combined co; board 5 CalciMedica / 2 Graybug; close expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/0001193125-22-290244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312522290244/d403773d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-290244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer